Research status, evidence boundaries and site notices

a1298c.com is an independent Panacea Bio Chem science-communications platform about the MTHFR A1298C variant (rs1801131) and the folate–methylation biochemistry around it. It exists because the public conversation about this variant is dominated by the stronger sibling variant (C677T), by marketing, and by associations that did not survive larger synthesis. The remedy is a readable, sourced, null-inclusive account.

The site is not affiliated with, sponsored by or endorsed by any genetic-testing laboratory, direct-to-consumer genomics company or supplement vendor. It sells nothing, recommends nothing, and interprets no individual’s genotype. Genotype results, homocysteine measurements and supplementation questions belong with a qualified clinician who knows the full clinical picture.

Every scientific claim traces to the references library: peer-reviewed literature via PubMed, the ClinicalTrials.gov registry, and the gnomAD allele-frequency resource via Ensembl REST — all fetch-verified on 2026-08-09. Evidence classes are stated per citation; null and unfavourable results are displayed at the same prominence as favourable ones, because they are the majority of the A1298C literature.

Where Panacea Bio Chem’s own formulation research is mentioned — the preservation and delivery stack for labile methylation-cycle molecules — it is presented as ongoing and exploratory, as candidate systems under evaluation, and it is never merged with the published clinical literature. No Panacea formulation is a treatment for any MTHFR-related question, and no Panacea trial result in this area exists or is claimed.